Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside of China. Unlike current drugs that hit only PD-1, this antibody aims at two ...

Outcome of Board Meeting - Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2025 and Recommendation of final dividend for the financial year 2024-25.